openPR Logo
Press release

Epoetin alfa and Darbepoetin alfa Has Maximum Share of 80% of Global Erythropoietin Drugs Market Revenue.

02-20-2019 06:53 PM CET | Health & Medicine

Press release from: Allied Market Research

Epoetin alfa and Darbepoetin alfa Has Maximum Share of 80%

Erythropoietin is a glycoprotein hormone synthesized in the bone marrow that controls and regulates the mechanism of erythropoiesis (production of red blood cells). This erythropoietin (EPO) drugs are used for the treatment of chemotherapy-induced anemia; anemia is a common side-effect occurring due to chemotherapy of End Stage Renal Diseases (ESRD), cancer and HIV. Improved recombinant DNA technology has led to the development of synthetic forms of erythropoietin such as epoetin alfa, epoetin beta, darbepoetin alfa, epoetin omega, and epoetin delta among the others.

Get the Sample:

Erythropoietin Drugs Market Report, published by Allied Market Research, forecasts that the global market is expected to garner $11.9 billion by 2020, registering a CAGR of 9.7% during the period 2014 - 2020. Darbepoetin alfa is the fastest growing drug class at a CAGR of 12.9% during the forecast period, owing to its high potency and minimal side-effects.

Rising incidences of Cancer, ESRD (End Stage Renal Disease), and HIV have largely contributed to the overwhelming demand for EPO drugs. Approximately 20% of the patients suffering from Cancer/HIV and ~70% of the patients suffering from ESRD undergo chemotherapy, which induces anemia in such patients, requiring EPO treatment.

Despite this, the market has nevertheless witnesses restraints due to high priced EPO drugs resulting in minimal adoption. However, commercialization of EPO biosimilars would eventually ease the influence of restraints and fuel the market growth, primarily across the developing regions.

For Purchase Inquiry:

Key findings of Erythropoietin Drugs Market:
Europe led the global EPO drug market in 2013 closely followed by North America.

Asia Pacific EPO drugs market is projected to grow at a CAGR of 13.3% during the forecast period, fastest among the four geographies.

Currently, Anemia Therapeutics (Cancer and HIV treatment) market leads the overall EPO drugs market; however, kidney therapeutic segment would emerge as the largest market segment by 2020.

Originator companies are investing in R&D for expanding product i.e. EPO drug applications to newer disorders such as neural diseases and in wound healing.

EPO drugs market is witnessing high commercialization of biosimilars for the 'off-patent' drug namely Erythropoietin alfa.

The first EPO drug - Epogen (Erythropoietin alfa), launched by Amgen, has witnessed patent expiry in 2014. Following this, a number of a biosimilar.

Erythropoietin alfa has been launched by major companies such as Biocon, Ranbaxy, Emcure Pharmaceuticals.

In addition, Amgen currently owns the patent Aranesp for Darbepoetin alfa; which is expected to expire by 2016, thus, calling for the launch of Darbepoetin Alfa biosimilars.

Some of the leading players operating in the EPO drug market are
- Amgen Inc.
- Johnson & Johnson
- Roche, LG Life Sciences Ltd.
- Biocon, Intas Pharmaceuticals
- Teva Pharmaceutical Industries Ltd.
- Ranbaxy Laboratories Ltd.
- Celltrion, Inc.

About Us:-

Allied Market Research (AMR) is a full-service market research and business consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact Us:-

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Epoetin alfa and Darbepoetin alfa Has Maximum Share of 80% of Global Erythropoietin Drugs Market Revenue. here

News-ID: 1604539 • Views: 4055

More Releases from Allied Market Research

Diphtheria, Tetanus, and Pertussis (DTP) Vaccine Market Expected to Reach $7.05 …
According to a new report published by Allied Market Research, titled, “Diphtheria, Tetanus, and Pertussis (DTP) Vaccine Market by Product, Age Group, and End User: Opportunity Analysis and Industry Forecast, 2020–2027," the global Diphtheria, Tetanus, and Pertussis Vaccine market was valued at $ 4,758.8 million in 2019 and is expected to reach $ 7,054.4 million by 2027, with a CAGR of 5.1% from 2020-2027. The DTaP segment accounted for major
Burn Care Market Expected to Reach $3,134 Million by 2027
According to a new report published by Allied Market Research, titled, “Burn care Market by Product, Depth of Burn, and End User: Opportunity Analysis and Industry Forecast, 2020–2027," the global burn care market size was valued at $1,992 million in 2019, and is projected to reach $3,134 million by 2027, growing at a CAGR of 5.6% from 2020 to 2027. Click Here To Access Free Sample Report: Burns are injuries
Drug Delivery Devices Market projected to Cross $26.7 Billion by 2026
Drug Delivery Devices Market size was valued at $19 billion in 2018, and is expected to reach $26.7 billion by 2026, registering a CAGR of 4.3% from 2019 to 2026. Drugs are used to improve health and to extend lives. However, the medications can be taken in various ways, including by swallowing, by absorption, by inhalation, through the skin, and by intravenous injection. For this, the drug delivery devices are developed,
Pharmaceutical Filtration Market on Position to Hit $7.74 Billion by 2026
Pharmaceutical filtration is defined as a filtration process to separate suspended particles from a medium or solution by passing them through a membrane. They reduce or eliminate the bacteria or other microorganisms in process components. The filtration process can be combined with other pharmaceutical manufacturing operations. Pharmaceutical filters are used in the production of small molecule ingredients such as active pharmaceutical ingredients (APIs) and pharmaceutical excipients. In addition, it is

All 5 Releases

More Releases for EPO

EPO biomarkers Market Size, Share, Analysis, Industry Report and Forecast 2018-2 …
Erythropoietin (EPO) is a hormone that is produced from the kidney inside the human body. EPO biomarkers Market are used to increase the growth of red blood cells in the body by stimulating the bone marrow. Some of the EPO biomarkers available in the market are epoetin alfa, epoetin beta, epoetin zeta, epoetin theta, recombinant human erythropoietin, and darbepoetin alfa. Erythropoietin alfa is used to treat anemia and cancer
Global EPO Biomarkers Market Research and Forecast 2018-2023
Global EPO biomarkers market size, market intelligence, market trends, research and analysis report by biomarker (erythropoietin alfa, beta, zeta, theta, recombinant human erythropoietin, darbepoetin alfa) by applications (end-stage renal disorder, cancers, rheumatoid arthritis, aids, myelodysplastic syndrome, neurology, hematology) forecast 2018-2023 According to the OMR analysis, the global EPO biomarkers Market is expected to grow impressively during 2018-2023. The global EPO biomarkers market is segmented on the basis of biomarker type, applications,
Quercetin Market Global Forecast 2018 | Studied By Monteloeder, EPO S.r.l., King …
UpMarketResearch published an exclusive report on “Quercetin market” delivering key insights and providing a competitive advantage to clients through a detailed report. The report contains 112 pages which highly exhibits on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability. This report focuses on the Quercetin market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa.
Global Erythropoietin (EPO) Market 2017 - Johnson & Johnson, Roche, Kyowa Hakko …
Global Erythropoietin (EPO) market Report offers decisive insights into the overall Erythropoietin (EPO) industry along with the market dimensions and evaluation for the duration 2017 to 2022. The forenamed research study covers extensive analysis of various Erythropoietin (EPO) industry segments based on the type of applications, type of product Components and services, and different geographical regions. Erythropoietin, also known as EPO, hematopoietin, or hemopoietin, is a glycoprotein hormone that controls
EPO Biosimilars - The Future of Erythropoietin Market
ReportsWorldwide has announced the addition of a new report title EPO Biosimilars - The Future of Erythropoietin Market to its growing collection of premium market research reports. Erythropoietin is a hormone produced by healthy kidneys. This hormone prompts the bone marrow to make the red blood cells, which then carry oxygen throughout the body. Erythropoietin is used to treat anemia resulting from kidney failure or cancer treatment. It is considered to
Global Erythropoietin (EPO) Market with Focus on Asia: Industry Analysis & Outlo …
Erythropoietin is a substance produced by the kidney that leads to the formation of red blood cells in the bone marrow. It is a glycoprotein hormone which regulates erythropoiesis (Red Blood Cell production). For erythrocyte precursors present in the bone marrow, EPO acts as a cytokine. Commonly referred to as hematopoietin or hemopoietin, erythropoietin is also known to have other biological functions, such as involvement in the wound healing cycle